Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

摘要: The incidence, pathogenesis, consequences and treatment of mammalian target rapamycin (mTOR) inhibitor dyslipidemia are not well described. We conducted a systematic review randomized controlled trials reporting cholesterol triglycerides in mTOR versus non-mTOR immunosuppressive regimens kidney transplant recipients. All but one 17 reported higher levels triglycerides, or an increased prevalence with lipid-lowering agents. Approximately 60% inhibitor-treated patients received agents (2-fold than controls). There appeared to be little difference between dyslipidemias caused by sirolimus (14 trials) everolimus (3 trials). It was difficult determine the extent which declines lipids over time posttransplant were due therapy, changes doses and/or discontinuations inhibitors. From four that measured lipoproteins, it at least some increase total inhibitors low-density lipoprotein cholesterol. What direct indirect effects have on atherosclerotic cardiovascular disease unknown. However, absence necessary clinical trials, should managed, as would nontransplant high risk for disease.